Merck spinoff company Organon completed its acquisition of Alydia Health, a medical device company focused on postpartum hemorrhage and abnormal postpartum uterine bleeding June 16.
Postpartum hemorrhage is one of the most common complications of birth, requiring pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions.
Globally, 40,510 women died due to PPH in 2016, according to a study by Our World in Data.
“Organon’s acquisition of Alydia Health expands our portfolio into the medical device category and underscores our commitment to identify options for women’s unmet medical needs. This acquisition brings us one step closer to our vision of a better and healthier every day for every woman around the world,” said Organon Chief Executive Officer Kevin Ali in a prepared statement.
Jersey City-based Organon announced plans to acquire Alydia Health in March for a total consideration of $240 million, including a $215 million cash payment plus a $25 million contingent milestone payment. Of the $215 million, $50 million was paid by Merck and $165 million paid by Organon.
